Cytokines at the research-clinical interface: Potential applications

Blood Reviews

Volumn 10, Issue 3, 1996, Pages 189-200

  Holyoake, T L ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; MILODISTIM; STEM CELL FACTOR; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; GENE THERAPY; HEMATOPOIESIS; HUMAN; LYMPHOPOIESIS; MAST CELL; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; THROMBOCYTOPENIA; URTICARIA;

EID: 0029807199     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(96)90026-0     Document Type: Article

References (117)

1. Pluznik DH, Sachs L. The cloning of normal 'mast' cells in tissue culture. J Cellul Compar Physiol 1965; 66: 319-324.
2. Metcalf D. Hematopoietic regulators: redundancy or subtlety? Blood 1993; 82: 3515-3523.
3. Qiu F, Ray P, Brown K et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988; 7: 1003-1011.
4. Ihle JN, Witthuhn B, Tang B, Quelle FW. Cytokine receptors and signal transduction. In: Brenner M. ed. Cytokines and Growth Factors, vol 7. London: Baillière-Tindall, 1994: 17-48.
5. Zurawski G, de Vries JE. Interleukin 13, an interleukin4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunology Today 1994; 15: 19-26.
6. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exper Med 1989; 170: 2081-2095.
7. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibiting factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science 1990; 248: 1230-1234.
8. Vieira P, de Waal-Malefyt R, Dang MW et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1. Proc Nat Acad Sci USA 1991; 88: 1172-1176.
9. Ho ASY, Liu Y, Khan TA, Hau DH, Bazan JF. A receptor for interleukin 10 is related to interferon receptors. Proc Nat Acad Sci USA 1993; 90: 11267-11271.
10. Brandon EP, Idzerda RL, McKnight GS. Targeting the mouse genome: a compendium of knockouts (part I, II & III). Curr Biol 1995; 5(6, 7, 8): 625-634, 758-765, 873-881.
11. Yoshida H, Hayashi S-I, Kunisada T et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345: 442-444.
12. Russell ES. Hereditary anaemias of the mouse: a review for geneticists. Advances in Genetics 1979; 20: 357-459.
13. Lieschke GJ, Grail D, Hodgson G et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737-1746.
14. Stanley E, Lieschke GJ, Grail D et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Nat Acad Sci USA 1994; 91: 5592-5596.
15. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265: 1445-1447.
16. de Sauvage FJ, Hass PE, Spencer SD et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-538.
17. Ozer H, Miller LL, Anderson JR et al. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12: 2471-2508.
18. Boogaerts MA, Demuynck HM. Consensus on the clinical use of myeloid growth factors. Curr Opin Hematol 1996; 3:241-246.
19. Anderson DM, Lyman SD, Baird A et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990; 63: 235-243.
20. Copeland NG, Gilbert DJ, Cho BC et al. Mast cell growth factor maps near the Steel locus on mouse chromosome 10 and is deleted in a number of Steel alleles. Cell 1990; 63: 175-183.
21. Huang E, Nocka K, Beier DR et al. The hematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990; 63: 225-233.
22. Martin FH, Suggs SK, Langley KE et al. Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 1990; 63: 203-211.
23. Williams DE, Eisenman J, Baird A et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167-174.
24. Zsebo KM, Wypych J, McNiece IK et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990; 63: 195-201.
25. Zsebo KM, Williams DA, Geissler EN et al. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990; 63: 213-224.
26. Williams DE, deVries P, Namen AE, Widmer MB, Lyman SD. The Steel Factor. Devel Biol 1992; 151: 368-376.
27. de Vries P, Brasel KA, Eisenman JR, Alpert AR, Williams DE. The effect of recombinant mast cell growth factor on purified murine hematopoietic stem cells. J Exper Med 1991; 173: 1205-1211.
28. Ogawa M, Matsuzaki Y, Nishikawa S et al. Expression and function of c-kit in hemopoietic progenitor cells. J Exper Med 1991; 174: 63-71.
29. Tsuji K, Zsebo KM, Ogawa M. Enhancement of murine blast cell colony formation in culture by recombinant rat stem cell factor, ligand for c-kit. Blood 1991; 78: 1223-1229.
30. Heyworth CM, Whetton AD, Nicholls S, Zsebo K, Dexter TM. Stem cell factor directly stimulates the development of enriched granulocyte-macrophage colony-forming cells and promotes the effects of other colony-stimulating factors. Blood 1992; 80: 2230-2236.
31. Lowry PA, Zsebo KM, Deacon DH, Eichman CE, Quesenberry PJ. Effects of rrSCF on multiple cytokine responsive HPP-CFC generated from Sca+ Lin-Murine hematopoietic progenitors. Exper Hematol 1991; 19: 994-996.
32. Lowry PA, Deacon D, Whitefield P, McGrath HE, Quesenberry PJ. Stem cell factor induction of in vitro murine hematopoietic colony formation by 'subliminal' cytokine combinations: the role of 'anchor factors'. Blood 1992; 80: 663-669.
33. Anderson DM, Williams DE, Tushinski R et al. Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24. Cell Growth and Differentiation 1991; 2: 373-378.
34. Dai CH, Krantz SB, Zsebo KM. Human burst-forming units-erythroid need direct interaction with Stem Cell Factor for further development. Blood 1991; 10: 2493-2497.
35. Briddell RA, Bruno E, Cooper RJ, Brandt JE, Hoffman R. Effect of c-kit ligand on in vitro human megakaryocytopoiesis. Blood 1991; 78: 2854-2859.
36. Ulich TR, del Castillo J, Yi ES et al. Hematologic effects of stem cell factor in vivo and in vitro in rodents. Blood 1991; 78: 645-650.
37. Zsebo KM, Smith KA, Hartley CA et al. Radio protection of mice by recombinant rat stem cell factor. Proc Nat Acad Sci USA 1992; 89: 9464-9468.
38. Schuening FG, Appelbaum FR, Deeg HJ et al. Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 1993; 81: 20-26.
39. Briddell RA, Hartley CA, Smith KA, McNiece IK. Recombinant rat stem cell factor synergises with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilise peripheral blood progenitor cells that have enhanced repopulating potential. Blood 1993; 82: 1720-1723.
40. Andrews RG, Briddell RA, Knitter GH et al. In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells. Blood 1994; 84: 800-810.
41. de Revel T, Appelbaum FR, Storb R et al. Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994; 83: 3795-3799.
42. Yan XQ, Hartley CA, McElroy P, Chang A, McCrea C, McNiece I. Peripheral blood progenitor cells mobilized by recombinant human granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by serial transplantation in mice. Blood 1995; 85: 2303-2307.
43. Glaspy J. Clinical applications of stem cell factor. Curr Opin Hematol 1996; 3: 223-229.
44. Rosnet O, Mattei M-G, Marchetto S, Birnbaum D. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 1991; 9: 380-385.
45. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGF/CSF1R family. Oncogene 1991; 6: 1641-1650.
46. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143-1152.
47. Small D, Levenstein M, Kim E et al. STK-1, the human homolog of flk-2/flt3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Nat Acad Sci USA 1994; 91: 459-463.
48. Lyman SD, Williams DE. Biology and potential clinical applications of flt3 ligand. Curr Opin Hematol 1995; 2: 177-181.
49. Lyman SD, James L, Bos TV et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75: 1157-1167.
50. Hannum C, Culpepper J, Campbell D et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of hematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643-648.
51. Johansson B, Billstrom R, Mauritzson N, Mitelman F. Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. Cancer Genet Cytogenet 1994; 74: 62-65.
52. Lyman SD, Brasel K, Rousseau A-M, Williams DE. The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor. Proceedings of the Metcalf Forum: Polyfunctionality of hematopoietic regulators 1994; 99-110.
53. Brasel K, Rousseau AM, de Vries P, Lyman SD, Williams DE. Recombinant flt3 ligand enhances hematopoiesis in myeloid and B-lymphoid long term bone marrow cultures. Exper Hematol 1994; 22: 736.
54. Petzer AL, Hogge DE, Lansdorp PM, Reid DS, Eaves CJ. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Nat Acad Sci USA 1996; 93: 1470-1474.
55. Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. Flt3 ligand (FL) is a potent inducer of proliferation of highly quiescent human bone marrow CD34+ CD38-cells. Blood 1995; 86 (suppl 1): 1677a.
56. Winton EF, Bucur SZ, Bray RA et al. The hematopoietic effects of recombinant human (rh) Flt3 ligand administered to non-human primates. Blood 1995; 86 (suppl 1): 1681a.
57. Ashihara E, Shimazaki C, Sudo Y et al. Flt-3 ligand synergistically enhances the in vivo response to G-CSF for mobilizing hematopoietic stem/progenitor cells into blood in mice. Blood 1995; 86 (suppl 1):429a.
58. Fletcher FA, Juan T, Lacey D et al. Chronic over-expression of murine flt3/flk2 ligand in mice results in increased circulating white blood cell levels and abnormal lymphoreticular cell infiltrates associated with splenic fibrosis. Blood 1995; 86 (suppl 1):73a.
59. Dao MA, Hannum C, Nolta JA, Kohn DB. Flt3 ligand preserves viability of human hematopoietic stem cells during in vitro transduction. Blood 1995; 86 (suppl 1): 1678a.
60. Vigon I, Mornon J-P, Cocault L et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Nat Acad Sci USA 1992; 89: 5640-5644.
61. Wendling F, Maraskovsky E, Debili N et al. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571-574.
62. Kaushansky K, Lok S, Holly RD et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-571.
63. Zeigler FC, de Sauvage F, Widmer HR et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-Mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994; 84: 4045-4052.
64. Ulich TR, Castillo J, Yin S et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86: 971-976.
65. Hokom MM, Lacey D, Kinstler OB et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486-4492.
66. Farese AM, Hunt P, Bone T, MacVittie TI Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86: 54-59.
67. Stead RB, Harker LA. Preclinical studies and potential clinical applications of c-mpl ligand. Curr Opin Hematol 1996; 3: 197-202.
68. Nichol JL, Hokom MM, Hornkohl A et al. Megakaryocyte growth and development factor: analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95: 2973-2978.
69. Basser R, Clarke K, Fox R et al. Randomized, double-blind, placebo-controlled phase 1 trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) administered to patients with advanced cancer before and after chemotherapy: early results. Blood 1995; 86 (suppl 1):1014a.
70. Paul SR, Bennett F, Calvetti JA et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Nat Acad Sci USA 1990; 87: 7512-7516.
71. Kawashima I, Takiguchi Y. Interleukin-11: a novel stroma-derived cytokine. Progr Growth Factor Res 1992; 4: 191-206.
72. Hilton DJ, Hilton AA, Raicevic A et al. Cloning of a murine IL-11 receptor a-chain; requirement for gp 130 for high affinity binding and signal transduction. EMBO J 1994; 13: 4765-4775.
73. Cherel M, Sorel M, Lebeau B et al. Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11. Blood 1995; 86: 2534-2540.
74. Anderson KC, Morimoto C, Paul SR et al. Interleukin-11 promotes accessory cell-dependent B-cell differentiation in humans. Blood 1992; 80: 2797-2804.
75. Tsuji K, Lyman SD, Sudo T, Clark SC, Ogawa M. Enhancement of murine hematopoiesis by synergistic interactions between Steel Factor (ligand for c-kit), interleukin-11, and other early acting factors in culture. Blood 1992; 79: 2855-2860.
76. Quesniaux VFJ, Clark SC, Turner K, Fagg B. Interleukin-11 stimulates multiple phases of erythropoiesis in vitro. Blood 1992; 80: 1218-1223.
77. Musashi M, Yang Y-C, Paul SR, Clark SC, Sudo T, Ogawa M. Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Nat Acad Sci USA 1991; 88: 765-769.
78. Du XX, Williams DA. Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood 1994; 83: 2023-2030.
79. Du XX, Doerschuk CM, Orazi A, Williams DA. Bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1994; 83: 33-37.
80. Keith JC, Albert L, Sonis ST, Pfeiffer CJ, Schaub RG. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 1994; 12 Suppl 1:79-90.
81. Potten CS. Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 1995; 62: 356-361.
82. Kaye JA. Clinical development of recombinant human interleukin-11 to treat chemotherapy-induced thrombocytopenia. Curr Opin Hematol 1996; 3: 209-215.
83. Mosmann TR, Cherwinski H, Bond MW et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348.
84. Krenger W, Ferrara JLM. Dysregulation of cytokines during graft-versus-host disease. J Hematother 1996; 5: 3-14.
85. Yokota T, Otsuda T, Mosmann T et al. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell and T-cell-stimulating activities. Proc Natl Acad Sci USA 1986; 83: 5894-5898.
86. Brown KD, Zurawski SM, Mosmann TR, Zurawski G. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 1989; 142: 679-687.
87. Montaner LJ, Doyle AG, Collin M et al. Interleukin 13 inhibits human immunodeficiency virus type 1 production in primary blood-derived human macrophages in vitro. J Exper Med 1993; 178: 743-747.
88. de Vries JE, Gauchat JF, Aversa G, Punnonen J, Yssel H. Regulation of IgE synthesis by cytokines. Curr Opin Immunol 1991; 3: 851-858.
89. Kopf M, le Gros G, Bachman M, Lamers MC, Bluethmann H, Kolher G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 368: 339-342.
90. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Resp Cell Molec Biol 1995; 12: 254-259.
91. Huhn RD, Radwanski E, O'Connell SM et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87: 699-705.
92. de Waal MR, Haanen J, Spits H et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exper Med 1991; 174: 915-924.
93. Geissler K. Current status of clinical development of interleukin-10. Curr Opin Hematol 1996; 3: 203-208.
94. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
95. Howard M, Muchamel T, Andrade S, Menon S. Interleukin-10 protects mice from lethal endotoxemia. J Exper Med 1993; 177: 1205-1208.
96. Chernoff AE, Granowitz EV, Shapiro L et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 5492.
97. Namen AE, Schmierer AE, March RW et al. B cell precursor growth-promoting activity: purification and characterization of a growth-factor active on lymphocyte precursors. J Exper Med 1988; 167: 988-1002.
98. Komschlies KL, Grzegorzewski KJ, Wiltrout RH. Diverse immunological and hematological effects of interleukin 7: implications for clinical application. J Leuk Biol 1995; 58: 623-633.
99. Borger P, Kauffman HF, Postma DS, Vellenga E. IL-7 differentially modulates the expression of IFN-γ and IL-4 in activated human T lymphocytes by transcriptional and posttranscriptional mechanisms. J Immunol 1996; 156: 1333-1338.
100. Jacobsen FW, Veiby OP, Skjonsberg C, Jacobsen SEW. Novel role of interleukin 7 in myelopoiesis: stimulation of primitive murine hematopoietic progenitor cells. J Exper Med 1993; 178: 1777-1782.
101. Grzegorzewski KJ, Komschlies KL, Jacobsen SEW, Ruscetti FW, Keller JR, Wiltrout RH. Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7. J Exper Med 1995; 181: 369-374.
102. Grabstein KH, Waldschmidt TJ, Finkelman FD et al. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J Exper Med 1993; 178: 257-264.
103. Sudo T, Nishikawa S, Ohno N et al. Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Nat Acad Sci USA 1993; 90: 9125-9129.
104. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exper Med 1995; 181: 1519-1526.
105. Peschon JJ, Morrissey PJ, Grabstein KH et al. Early lymphocyte expansion is severely impaired in interleukin-7 receptor-deficient mice. J Exper Med 1994; 180: 1955-1960.
106. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exper Med 1993; 177: 305-316.
107. Gubler U, Chua AO, Schoenhaut DS et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Nat Acad Sci USA 1991; 88: 4143-4147.
108. Wolf SF, Temple PA, Kobayashi M et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074-3081.
109. Chua AO, Chizzonite R, Desai BB et al. Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994; 153: 128-136.
110. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241-251.
111. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 1994; 2: 96-106.
112. Bellone G, Trincheri G. Dual stimulatory and inhibitory effect of NK stimulatory factor/IL-12 on human hematopoiesis. J Immunol 1994; 153: 930-937.
113. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exper Med 1993; 177: 1505-1509.
114. Zitvogel L, Tahara H, Robbins PD et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393-1403.
115. Chougnet C, Shearer GM. Potential clinical applications of interleukin-12. Curr Opin Hematol 1996; 3: 216-222.
116. Cancer trial of interleukin-12 halted. Science 1995; 268: 1555.
117. IL-12 deaths: explanation and a puzzle. Science 1995; 270: 908.